{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:02:30Z","timestamp":1792000950650,"version":"4.4.0"},"reference-count":50,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2016.00467","type":"journal-article","created":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T03:52:24Z","timestamp":1480996344000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis"],"prefix":"10.3389","volume":"7","author":[{"given":"Gabriella","family":"Giancane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Minoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Dav\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bracciolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2016,12,6]]},"reference":[{"key":"B1","first-page":"343","article-title":"Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR)","volume":"35","author":"Behrens","year":"2008","journal-title":"J. Rheumatol."},{"key":"B2","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J. Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.12703\/p6-21","article-title":"Treatment advances in systemic juvenile idiopathic arthritis","volume":"6","author":"Beukelman","year":"2014","journal-title":"F1000Prime Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/art.22416","article-title":"The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis","volume":"56","author":"Bleesing","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrrheum.2013.2","article-title":"Paediatric rheumatology: biologic therapy for systemic juvenile idiopathic arthritis\u2013times they are a'changing!","volume":"9","author":"Buckland","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1546-0096-7-21","article-title":"Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist","volume":"7","author":"Canna","year":"2009","journal-title":"Pediatr. Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/art.20946","article-title":"Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?","volume":"52","author":"de Benedetti","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/B978-0-323-24145-8.00016-8","article-title":"Systemic juvenile idiopathic arthritis","volume-title":"Textbook of Pediatric Rheumatology, 7th Edn.","author":"De Benedetti","year":"2016"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/nejmoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N.Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/art.24777","article-title":"Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis","volume":"60","author":"Giannini","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/01.bor.0000381996.69261.71","article-title":"Macrophage activation syndrome: advances towards understanding pathogenesis","volume":"22","author":"Grom","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheum."},{"key":"B16","first-page":"935","article-title":"Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis","volume":"32","author":"Kimura","year":"2005","journal-title":"J. Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.autrev.2012.07.022","article-title":"Systemic juvenile idiopathic arthritis","volume":"12","author":"Martini","year":"2012a","journal-title":"Autoimmun. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","article-title":"It is time to rethink juvenile idiopathic arthritis classification and nomenclature","volume":"71","author":"Martini","year":"2012b","journal-title":"Ann. Rheum. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12891-015-0555-9","article-title":"Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF-\u03b1 therapy","volume":"16","author":"Martini","year":"2015","journal-title":"BMC Musculoskelet. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","article-title":"Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease","volume":"27","author":"Masters","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","article-title":"Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions","volume":"7","author":"Mellins","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3899\/jrheum.141261","article-title":"Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"42","author":"Minoia","year":"2015","journal-title":"J. Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheum."},{"key":"B27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheum."},{"key":"B29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/rheumatology\/ken030","article-title":"Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)","volume":"47","author":"Ohlsson","year":"2008","journal-title":"Rheumatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3899\/jrheum.141567","article-title":"Anakinra in systemic juvenile idiopathic arthritis: a single-center experience","volume":"42","author":"Pardeo","year":"2015","journal-title":"J. Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J. Exp. Med."},{"key":"B32","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J. Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun."},{"key":"B36","article-title":"Development and initial validation of classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"12","author":"Ravelli","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American college of rheumatology\/paediatric rheumatology international trials organisation collaborative initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00002281-200209000-00012","article-title":"Macrophage activation syndrome","volume":"14","author":"Ravelli","year":"2002","journal-title":"Curr. Opin. Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/nejmoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N.Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/nejme1212640","article-title":"A new era in the treatment of systemic juvenile idiopathic arthritis","volume":"367","author":"Sandborg","year":"2012","journal-title":"N.Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","article-title":"Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles","volume":"61","author":"Shimizu","year":"2013","journal-title":"Cytokine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3899\/jrheum.120842","article-title":"Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept","volume":"40","author":"Solari","year":"2013","journal-title":"J. Rheumatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1517\/14712598.2010.532785","article-title":"The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis","volume":"10","author":"Swart","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.berh.2009.08.003","article-title":"Systemic JIA: new developments in the understanding of the pathophysiology and therapy","volume":"23","author":"Vastert","year":"2009","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"B47","first-page":"2071","article-title":"Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis","volume":"31","author":"Verbsky","year":"2004","journal-title":"J. Rheumatol."},{"key":"B48","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J. Rheumatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/1759720X12455960","article-title":"Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis","volume":"4","author":"Yokota","year":"2012","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/rhu.0b013e3181a4f459","article-title":"Anakinra for systemic juvenile arthritis: the Rocky Mountain experience","volume":"15","author":"Zeft","year":"2009","journal-title":"J. Clin. Rheumatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2016.00467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T05:18:33Z","timestamp":1498367913000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2016.00467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,6]]},"references-count":50,"URL":"https:\/\/doi.org\/10.3389\/fphar.2016.00467","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,6]]}}}